Profile data is unavailable for this security.
About the company
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
- Revenue in USD (TTM)0.00
- Net income in USD-10.27m
- Incorporated2004
- Employees31.00
- LocationEledon Pharmaceuticals Inc19800 MACARTHUR BLVD., SUITE 250IRVINE 92612United StatesUSA
- Phone+1 (949) 238-8090
- Fax+1 (302) 655-5049
- Websitehttps://eledon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caribou Biosciences Inc | 9.30m | -157.13m | 148.61m | 147.00 | -- | 1.05 | -- | 15.99 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
| ProQR Therapeutics NV | 19.08m | -50.53m | 149.59m | 166.00 | -- | 2.26 | -- | 7.84 | -0.486 | -0.486 | 0.1837 | 0.6289 | 0.139 | -- | 9.70 | 114,938.80 | -36.82 | -29.87 | -53.74 | -35.27 | -- | -- | -264.83 | -501.81 | -- | -- | 0.2242 | -- | 105.20 | 58.84 | 1.27 | -- | 19.58 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 762.00k | -50.77m | 149.82m | 62.00 | -- | 2.70 | -- | 196.62 | -0.9144 | -0.9144 | 0.0137 | 0.9926 | -- | -- | -- | 12,290.32 | -- | -61.12 | -- | -66.78 | -- | -- | -6,662.99 | -1,963.00 | -- | -- | 0.00 | -- | -- | -- | 74.84 | -- | 37.04 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -58.01m | 155.01m | 33.00 | -- | 7.56 | -- | -- | -0.8938 | -0.8938 | 0.00 | 0.2407 | 0.00 | -- | -- | 0.00 | -68.07 | -48.63 | -75.01 | -52.10 | -- | -- | -- | -1,201.96 | -- | -73.28 | 0.7327 | -- | -100.00 | -- | 30.44 | -- | -39.67 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -133.35m | 155.07m | 61.00 | -- | 1.66 | -- | -- | -2.21 | -2.21 | 0.00 | 1.54 | 0.00 | -- | -- | 0.00 | -65.18 | -33.77 | -72.61 | -35.61 | -- | -- | -- | -21,273.47 | -- | -- | 0.2475 | -- | -- | -- | -95.39 | -- | -- | -- |
| Century Therapeutics Inc | 113.34m | -26.48m | 156.46m | 140.00 | -- | 0.8783 | -- | 1.38 | -0.3086 | -0.3086 | 1.32 | 2.04 | 0.3579 | -- | -- | 809,550.00 | -8.36 | -33.69 | -8.95 | -36.94 | -- | -- | -23.36 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| Rani Therapeutics Holdings Inc | 1.20m | -28.32m | 156.76m | 105.00 | -- | -- | -- | 130.64 | -0.7906 | -0.7906 | 0.0322 | -0.1093 | 0.0447 | -- | -- | 11,428.57 | -177.34 | -64.50 | -603.19 | -106.31 | -- | -- | -3,966.50 | -6,123.18 | -- | -14.32 | 8.66 | -- | -- | 0.9816 | 11.63 | -- | -29.88 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -10.27m | 160.06m | 31.00 | -- | 3.42 | -- | -- | -0.0993 | -0.0993 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -65.28 | -46.29 | -73.32 | -48.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.95 | -- | -- | -- |
| Tharimmune Inc | 0.00 | -10.32m | 164.12m | 2.00 | -- | 5.09 | -- | -- | -4.11 | -4.11 | 0.00 | 0.854 | 0.00 | -- | -- | 0.00 | -159.36 | -169.40 | -225.01 | -410.04 | -- | -- | -- | -- | -- | -- | 0.0255 | -- | -- | -- | -30.89 | -- | -- | -- |
| Insight Molecular Diagnostics Inc | 4.40m | -60.78m | 164.25m | 46.00 | -- | -- | -- | 37.31 | -2.83 | -2.83 | 0.1643 | -0.3213 | 0.0771 | 5.67 | 18.85 | 95,695.65 | -106.49 | -41.57 | -124.80 | -46.86 | 54.73 | 24.70 | -1,380.69 | -2,290.77 | 2.73 | -171.82 | -- | -- | 25.15 | -- | -136.17 | -- | -10.88 | -- |
| Cartesian Therapeutics Inc | 1.93m | -50.61m | 166.42m | 66.00 | -- | -- | -- | 86.36 | -1.97 | -1.97 | 0.0743 | -1.38 | 0.0047 | -- | 0.6943 | 29,196.97 | -11.59 | -33.50 | -12.10 | -45.25 | -- | -- | -2,489.83 | -128.46 | -- | -- | -- | -- | 49.64 | 42.27 | 69.90 | -- | 186.63 | -- |
| Sagimet Biosciences Inc | 0.00 | -57.67m | 170.74m | 14.00 | -- | 1.43 | -- | -- | -1.79 | -1.79 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -38.04 | -40.69 | -39.78 | -43.01 | -- | -- | -- | -6,987.70 | -- | -- | 0.00 | -- | -100.00 | -- | -63.46 | -- | -- | -- |
| Editas Medicine Inc | 46.38m | -199.84m | 172.79m | 246.00 | -- | 12.27 | -- | 3.73 | -2.38 | -2.38 | 0.5454 | 0.1443 | 0.1753 | -- | 11.24 | 188,548.80 | -75.51 | -34.19 | -101.13 | -38.43 | -- | -- | -430.84 | -373.02 | -- | -- | 0.8145 | -- | -58.64 | 9.50 | -54.74 | -- | 7.43 | -- |
Data as of Feb 12 2026. Currency figures normalised to Eledon Pharmaceuticals Inc's reporting currency: US Dollar USD
37.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Sep 2025 | 6.29m | 8.38% |
| Coastlands Capital LPas of 19 Nov 2025 | 4.76m | 6.34% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.57m | 4.75% |
| RA Capital Management LPas of 30 Sep 2025 | 3.57m | 4.75% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 3.13m | 4.17% |
| Zimmer Partners LPas of 30 Sep 2025 | 1.83m | 2.43% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.37m | 1.82% |
| Sphera Funds Management Ltd.as of 30 Sep 2025 | 1.28m | 1.71% |
| Ensign Peak Advisors, Inc.as of 30 Sep 2025 | 1.26m | 1.69% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 1.16m | 1.54% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
